Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26689259 | 1.00 | GLP1R (0.52) | GLP1RCA1CA2SIRT5MEN1 | |
| SCHEMBL26689380 | 1.00 | GLP1R (0.52) | GLP1RCA1CA2SIRT5MEN1 | |
| SCHEMBL26689385 | 1.00 | GLP1R (0.52) | GLP1RCA1CA2SIRT5MEN1 | |
| SCHEMBL24667758 | 0.98 | GLP1R (0.55) | GLP1RCA1CA2SIRT5MEN1 | |
| SCHEMBL26689250 | 0.95 | GLP1R (0.49) | GLP1RCA1CA2SIRT5MEN1 | |
| SCHEMBL26689252 | 0.95 | GLP1R (0.49) | GLP1RCA1CA2SIRT5MEN1 | |
| SCHEMBL26689108 | 0.95 | GLP1R (0.49) | GLP1RCA1CA2SIRT5MEN1 | |
| SCHEMBL26689110 | 0.95 | GLP1R (0.49) | GLP1RCA1CA2SIRT5MEN1 | |
| SCHEMBL23077723 | 0.94 | CTSS (0.49) | GLP1RCA1CA2SIRT5MEN1 | |
| SCHEMBL15919180 | 0.94 | CTSS (0.49) | GLP1RCA1CA2SIRT5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023223097-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |